Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 2 art units • 3 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sphingotec GmbH maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 6 pending office actions. These actions are distributed across 2 distinct art units, indicating some technical breadth within the company's pharmaceutical filings. Having 6 pending office actions suggests a significant level of ongoing interaction with the USPTO, as the company seeks to secure its intellectual property in the biotechnology sector.
The prosecution involves 3 distinct examiners. SAOUD, CHRISTINE J is identified as the busiest examiner for the portfolio. This examiner is currently handling 4 pending office actions. This concentration shows that a majority of the company's pending workload is managed by a single examiner, despite the involvement of 3 distinct examiners across the portfolio. For a practitioner, this means that the outcomes for a large portion of the pending actions are currently dependent on the specific examination style of SAOUD, CHRISTINE J, while the remaining actions are split among other examiners. The 2 distinct art units involved further define the technical boundaries of the current prosecution.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 4 | 58.0% | +37.2% |
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| MARCSISIN, ELLEN JEAN | 1 | 34.5% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 37d overdue |
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | — |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | — |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 88d overdue |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 37d overdue |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | SAOUD, CHRISTINE J | 36d overdue |
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | — |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | — |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 4 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | — | §102§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 1645 | §112 | Final Rejection | 88d overdue | Pending | Dec 30, 2022 |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | 1677 | §101§112DP | Final Rejection | — | Pending | Sep 29, 2022 |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | 1645 | §102§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 1645 | §102§112 | Non-Final OA | 37d overdue | Pending | Feb 04, 2020 |
| 16315805 | ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE | SAOUD, CHRISTINE J | 1645 | §112 | Final Rejection | 36d overdue | Pending | Jan 07, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial